Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I—Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications
- 16 November 2017
- journal article
- research article
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 142 (1) , 17-25
Abstract
Context.—: Colorectal cancer (CRC) represents the third most-common cancer in developed countries and is a leading cause of cancer deaths worldwide. Two recognized pathways contribute to CRC development: a more-common chromosomal instability pathway and, in 15% of cases, a deficient mismatch repair or microsatellite instability–high (MSI-H) pathway. The MSI-H CRC can be associated with somatic or germline mutations. Microsatellite status has been recognized as a prognostic and predictive biomarker. Objectives.—: To summarize the molecular pathways of CRC, with an emphasis on the MSI (mismatch repair) pathway; the recommended MSI testing algorithms and interpretation; and the prognostic and predictive role of MSI-H status in personalized treatment, including adjuvant chemotherapy, targeted therapy, and immune checkpoint inhibitor therapy. Data Sources.—: A PubMed (US National Library of Medicine, Bethesda, Maryland) review was performed for articles pertaining to CRC, MSI and mismatch repair systems, molecular classification, immune response, programmed death receptor-1/programmed death ligand-1, and immunotherapy. Conclusions.—: Although the TNM classification of malignant tumor stage remains the key determinant of CRC prognosis and treatment, there are considerable stage-independent, interindividual differences in clinical outcome and therapy response by patients. In addition, MSI-H status has an important role in CRC management and can be reliably detected by molecular and immunohistochemistry techniques and genetic testing. Efforts must be made to identify whether MSI-H CRC is germline or sporadic to ensure appropriate treatment, accurate prognosis, and risk assessment for relatives. Microsatellite status has been recognized as a good prognostic indicator and is predictive of a poor response to 5-fluorouracil–based chemotherapy and a good response to programmed death ligand-1 inhibitor pembrolizumab in metastatic/refractory MSI-H CRC.Keywords
This publication has 46 references indexed in Scilit:
- The evolving role of microsatellite instability in colorectal cancer: A reviewCancer Treatment Reviews, 2016
- Molecular pathological classification of colorectal cancerVirchows Archiv, 2016
- Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite InstabilityImmunity, 2016
- How reliable is immunohistochemical staining for DNA mismatch repair proteins performed after neoadjuvant chemoradiation?Human Pathology, 2014
- Characterisation of Familial Colorectal Cancer Type X, Lynch syndrome, and non-familial colorectal cancerBritish Journal of Cancer, 2014
- Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumoursThe Journal of Pathology, 2013
- Relevance, Pathogenesis, and Testing Algorithm for Mismatch Repair–Defective Colorectal CarcinomasThe Journal of Molecular Diagnostics, 2012
- Update on the serrated pathway to colorectal carcinomaHuman Pathology, 2011
- Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysisEuropean Journal of Cancer, 2009
- Gastrointestinal cancer of the microsatellite mutator phenotype pathwayJournal of Gastroenterology, 2002